# Benchmark Adjudication Executive Summary (Remediated Phase A.1.2)

**Benchmark Artifact:** MediScanAI Evaluation Suite  
**Phase:** Phase A.1.2 — Evidence Provenance Remediation & Automated Re-audit  
**Status:** `preliminary_ai_annotated` (Reviewer Packet Ready for Human Clinical Adjudication)  
**Date:** October 14, 2026  
**Author:** Medical Evidence Research Engineer & Benchmark Data Integrity Auditor  

---

## 1. Overview and Deliverables

Under Phase A.1.2, all invalid DailyMed references identified during the Phase A.1.1 audit were remediated using live, verified FDA Structured Product Labeling (SPL) setids from the official DailyMed REST API. In addition, benchmark documentation was programmatically regenerated from the validated machine-readable datasets to achieve 100% exact parity.

### Key Artifacts in `evaluation/benchmark/research_adjudication/`:
1. `proposed_judgments.jsonl` — 62 proposed judgment records covering all 50 canonical cases with authentic regulatory URLs, preliminary status, and exact source citations.
2. `source_evidence.jsonl` — 35 unique primary source evidence entries linking every entity, symptom set, and negative control to its verified authoritative URL, publisher, date, excerpt, and supported claim.
3. `reviewer_packet.csv` — An easy-to-review 62-row tabular dataset for clinical annotators and benchmark auditors.
4. `case_coverage_report.md` — Programmatically generated case-by-case accounting across all 11 canonical categories, with zero discrepancies against the underlying JSONL dataset.
5. `source_remediation_report.md` — Complete audit trail of all 14 formerly invalid DailyMed setids, their verified replacements, and live HTTP/API verification results.
6. `judgment_change_log.md` — Explicit changelog documenting that 0 relevance grades were altered, preserving the established clinical relevance rubric.
7. `final_integrity_audit_report.md` — Comprehensive validation results, readiness decision, and non-interference confirmation.
8. `adjudication_summary.md` — This executive summary.

---

## 2. Quantitative Summary Statistics (Programmatically Derived)

### Proposed Relevance Grades Distribution
| Grade | Description | Count | Percentage of Evaluated Candidates |
|:---:|---|:---:|:---:|
| **Grade 3** | **Direct / Definitive Answer** (Exact brand match, single-ingredient generic, pathognomonic symptom profile) | 45 | 72.6% |
| **Grade 2** | **Highly Relevant Supporting Evidence** (Fixed-dose combination product, brand counterpart, non-specific differential presentation) | 11 | 17.7% |
| **Grade 1** | **Marginally Relevant Evidence** (Indirect secondary etiology: uremic pericarditis chest pain in renal failure) | 1 | 1.6% |
| **Grade 0** | **Irrelevant / Fictitious / Unsupported** (Negative controls: fictitious drugs, fictitious diseases, false curative claims) | 5 | 8.1% |
| **Total** | **All Proposed Adjudications** | **62** | **100.0%** |

### Human Review Triage Classification
| Review Requirement | Query Count | Candidate Rows | Domain & Scope | Permitted Reviewer Qualification |
|---|:---:|:---:|---|---|
| `none` | 25 cases | 37 rows | Drug brand lookup, unbranded generic lookup, active ingredient verification, negative controls | Technical auditor, non-medical benchmark annotator |
| `qualified_medical_review` | 25 cases | 25 rows | Disease symptom mapping, multi-symptom presentations, lay expression translation, ambiguous differentials | Board-certified physician, clinical pharmacist |
| **Total** | **50 cases** | **62 rows** | **Full Benchmark Representation** | **Strict Separation of Reviewer Competency** |

---

## 3. Retrieval Harness Performance & Channel Provenance

From the empirical multi-channel retrieval evaluation conducted on the benchmark (`top_k=5`):
- **Dual-Channel (`both`) Hits:** 11 candidates retrieved by both FAISS and Neo4j graph in the top 5.
- **Baseline-Only Hits:** 14 candidates retrieved solely by the FAISS dense index in the top 5 (primarily disease chunks).
- **Graph-Only Hits:** 7 candidates retrieved solely by Neo4j graph in the top 5 (unbranded generic substances and shared active ingredient queries).
- **Unretrieved Candidates (Top-5 Cutoff):** 25 candidates placed outside the top-5 cutoff (`baseline_rank: null, graph_rank: null`).
- **Negative Controls (Expected None):** 5 unanswerable negative control queries.
- All unretrieved candidates are preserved in `proposed_judgments.jsonl` with their true clinical grades to prevent artificial metric inflation and allow proper retrieval recall benchmarking.

---

## 4. Integrity and Compliance Checklist

- [x] **`entity_resolution/` Directory:** Treated as strictly off-limits; never inspected, read, searched, referenced, or imported.
- [x] **Production Retrieval Code:** Untouched (`app/core.py`, `app/retriever.py`, `app/graph/`, backend endpoints, FAISS indexes, and Neo4j schema remain unmodified).
- [x] **Source JSONL Datasets:** `data/drugs_faiss_data.jsonl` and `data/diseases_faiss_data.jsonl` remain untouched.
- [x] **Canonical Case Identities:** All 50 queries (`MED-BENCH-001` through `MED-BENCH-050`) preserved verbatim without alteration.
- [x] **Live Verified URLs:** All 14 DailyMed package insert URLs remediated with verified SPL setids resolving via HTTP 200 on the live DailyMed API.
- [x] **Annotation Status:** All proposed judgments marked strictly as `preliminary_ai_annotated`; `reviewed_at` is `null`; reviewer ID is `ai_research_assistant`. No claims of human review are made.
- [x] **Gold Judgments Untouched:** `evaluation/benchmark/gold_judgments.jsonl` remains an untouched, zero-byte file (size: 0 bytes).
- [x] **Zero Paid API Calls:** Conducted exclusively using local retrieval outputs and publicly accessible health registries.
- [x] **Zero Git Operations:** No commits, pushes, merges, resets, or dependency installations.
